IL5 and nasal cavity polyp: However, recent approval by regulatory agencies for biologic therapies that target Type 2 inflammation including dupilumab (an anti-IL-4α monoclonal antibody) (90), omalizumab (an anti-IgE monoclonal antibody), and mepolizumab (anti-IL-5) have been found to be efficacious at reducing nasal polyps in patients with CRSwNP.